Inside the research
ADMA Biologics, Inc.
ADMA Research profile · latest available data
Price overview
$9.38
▼ -0.14 (-1.5%)
| 52w hi | $20.38 |
|---|---|
| 52w lo | $7.60 |
| Vol | 3.57M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.15
| Short | -0.67 |
|---|---|
| Medium | +0.05 |
| Long | +0.49 |
computed 2026-09-27
Key fundamentals
ADMA Biologics, Inc.
Healthcare · Biotechnology
| Market cap | $2.10B |
|---|---|
| Enterprise value | $2.17B |
| Trailing P/E | 13.40x |
| Forward P/E | 9.94x |
| EV / EBITDA | 9.67x |
| P / S (ttm) | 4.10x |
| Profit margin | 33.0% |
| Return on equity | 41.9% |
| Revenue growth | +2.0% |
| Earnings growth | +14.3% |
| Debt / equity | 49.94 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.33 | |
| Sector | +0.13 | |
| Technical | -0.31 | |
| Earnings | +0.00 | |
| Sentiment | -0.17 |
macro × 1.00 · 2026-09-27
Business overview
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Risk Metrics
| Beta vs SPX | 1.09 |
|---|---|
| Corr SPX | 0.31 |
| Annual vol | 56.1% |
| Annual ret | -21.9% |
| Sharpe | -0.39 |
| Max DD | -69.0% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $16.75 |
|---|---|
| High / Low | $20.00 / $12.00 |
| Median | $17.50 |
| Analysts | 4 |
| Strong Buy | 0 | |
|---|---|---|
| Buy | 3 | |
| Hold | 1 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-07 | Mizuho | → Outperform |
| 2026-05-07 | Canaccord Genuity | → Buy |
| 2026-04-21 | Canaccord Genuity | → Buy |
| 2026-04-13 | Mizuho | → Outperform |
| 2026-03-26 | Cantor Fitzgerald | → Neutral |
| 2025-05-08 | Raymond James | → Strong Buy |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-06-02 | Shareholder Vote | read |
| 2026-05-06 | Earnings Release, Exhibits | read |
| 2026-05-04 | Other Material Event, Exhibits | read |
| 2026-03-27 | Reg FD Disclosure, Exhibits | read |
| 2026-03-02 | Reg FD Disclosure, Other Material Event… | read |
| 2026-02-25 | Earnings Release, Officer / Director Change… | read |
| 2026-01-12 | Earnings Release, Reg FD Disclosure… | read |
| 2025-11-05 | Earnings Release, Exhibits | read |
| 2025-08-06 | Material Agreement, Termination of Agreement… | read |
| 2025-06-04 | Shareholder Vote | read |
| 2025-05-07 | Earnings Release, Other Material Event… | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 9 |
| Top-5 share | 94.0% |
| HHI | 5,217 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $143.26M | 17.12M |
| Citadel Advisors | $13.56M | 1.62M |
| AQR Capital Management | $12.77M | 1.53M |
| Capital Research / Capital World | $9.82M | 1.17M |
| Millennium Management | $9.66M | 1.15M |
| Renaissance Technologies | $5.46M | 652.53K |
| Bridgewater Associates | $3.36M | 401.06K |
| Fidelity / FMR LLC | $3.26M | 389.52K |
| T. Rowe Price Group | $13.33K | 1.59M |
As of 2026-06-30
SEC Filings
The Long Run
FY 2012–2025 · 14 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $258.21M | +56.6% | |
| Gross profit | $292.76M | +87.2% | |
| Operating income | $191.44M | — | |
| Net income | $146.93M | -25.7% | |
| Cash from ops | $8.80M | — |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $9.55 | $9.62 | $9.23 | $9.38 | 3.57M |
| Sep 24 | $9.67 | $9.82 | $9.37 | $9.52 | 2.59M |
| Sep 23 | $9.81 | $9.84 | $9.43 | $9.70 | 2.60M |
| Sep 22 | $9.53 | $9.84 | $9.45 | $9.81 | 2.74M |
| Sep 21 | $9.19 | $9.54 | $9.10 | $9.51 | 2.86M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →